Related Experiment Video
Updated: May 5, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The Past, Present, and Future of Dyslipidemia: A Narrative Review
1Cardiology, Manoria Heart and Critical Care Hospital, Bhopal, IND.
Insights
Cardiovascular disease management in India is shifting towards precision lipidology. New guidelines and advanced therapies offer personalized strategies for early, aggressive prevention, especially in younger populations at high risk.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Preventive Cardiology
Background:
- Cardiovascular disease (CVD) is a leading global cause of death, with dyslipidemia as a key modifiable risk factor for atherosclerotic CVD.
- India faces a high burden of early-onset CVD, characterized by a distinct lipid profile including high triglycerides, low HDL-C, and sdLDL particles.
- Atherosclerosis pathophysiology is increasingly understood through the response-to-retention hypothesis, emphasizing ApoB lipoproteins in vascular inflammation.
Purpose of the Study:
- To review the evolving understanding of lipid metabolism and its role in atherosclerosis.
- To highlight the updated Lipid Association of India 2023 guidelines for CVD risk assessment and stratification.
- To discuss the expanding therapeutic landscape and future directions in precision lipidology for cardiovascular prevention.
Main Methods:
- Review of current literature on lipid science, atherosclerosis pathophysiology, and cardiovascular risk assessment.
- Analysis of the Lipid Association of India 2023 guidelines recommendations.
- Overview of established and emerging lipid-lowering therapies.
Main Results:
- The response-to-retention hypothesis offers a more comprehensive view of atherosclerosis than the cholesterol-centric model.
- The 2023 guidelines advocate for lifetime risk-based assessment using CACS, plaque imaging, and ABI for refined risk stratification.
- Therapeutic options have expanded significantly, enabling deeper and safer lipid reduction with novel agents.
Conclusions:
- Precision lipidology, integrating genomics, imaging, and advanced therapeutics, is crucial for early and individualized CVD prevention.
- Personalized, multimodal strategies are essential to address traditional and residual risk in India's younger populations.
- The future of lipid management focuses on sustained cardiovascular protection and improved public health outcomes through tailored interventions.
Abstract:
Cardiovascular disease (CVD) remains the leading global cause of death, with dyslipidemia as its most modifiable driver of atherosclerotic CVD. The burden is especially severe in India, where early-onset disease and a distinct lipid profile, marked by elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), and small dense low-density lipoprotein (sdLDL) particles, contribute to increased lifetime risk. The pathophysiology of atherosclerosis has evolved from the cholesterol-centric model to the response-to-retention hypothesis, highlighting the role of apolipoprotein B (ApoB)-containing lipoproteins in initiating vascular inflammation and plaque formation. Advances in lipid science have revealed complex interactions between lipid metabolism, endothelial dysfunction, and immune activation. The Lipid Association of India 2023 guidelines recommend lifetime risk-based assessment and early intervention using coronary artery calcium scoring (CACS), carotid and femoral plaque imaging, and ankle-brachial index (ABI) to refine risk stratification. Therapeutic options have expanded beyond statins to include ezetimibe, PCSK9 inhibitors, bempedoic acid, and RNA-based agents, offering deeper and safer lipid reduction. Emerging therapies targeting ANGPTL3, liver X receptor (LXR) β, and PPAR-β/δ pathways promise further innovation in lipid modulation. These developments mark a shift toward precision lipidology, integrating genomics, imaging, and long-acting therapeutics to enable early, aggressive, and individualized prevention. As India faces a rising tide of cardiovascular events in younger populations, the future of lipid management lies in personalized, multimodal strategies that address both traditional and residual risk, aiming for sustained cardiovascular protection and improved public health outcomes.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Atherosclerosis I: Introduction
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...